30th Mar 2005 12:40
Diageo PLC30 March 2005 30 March 2005 FRANZ B. HUMER TO JOIN THE DIAGEO BOARD Diageo plc announced today the appointment of Dr Franz B. Humer, Chairman andCEO of Roche, to the Diageo board, effective 1 April 2005. His appointment brings to seven the number of Diageo's independentnon-executive directors. He will be appointed to the Audit Committee,Remuneration Committee and Nomination Committee. Commenting on the appointment, Lord Blyth said: 'Franz is a highly respected international businessman and brings a variety ofhighly relevant complementary skills and experience. We are delighted towelcome him to the Diageo board.' -ends - Diageo media enquiries to: Isabelle Thomas +44 (0) 20 7927 5967 [email protected] Diageo investor relations enquiries to Catherine James +44 (0) 20 7927 5272 [email protected] Roche media enquiries to: Roche Group Media Office +41 61 688 88 88 [email protected] Notes to Editor: 1. Diageo's chairman is James Blyth. Other non-executive directors are: LordHollick (Senior Independent Director and chairman of the RemunerationCommittee), Maria Lilja, William Shanahan, Jonathan Symonds (chairman of theAudit Committee), Todd Stitzer and Paul Walker. Executive members of the boardare Paul Walsh (CEO), Nick Rose (CFO). 2. Diageo is the world's leading premium drinks business. With its globalvision, and local marketing focus, Diageo brings to consumers an outstandingcollection of beverage alcohol brands across the spirits, wine and beercategories including Smirnoff, Guinness, Johnnie Walker, Baileys, J&B, Cuervo,Captain Morgan and Tanqueray, and Beaulieu Vineyard and Sterling Vineyardswines. Diageo trades in some 180 countries around the world and is listed onboth the New York Stock Exchange (DEO) and the London Stock Exchange (DGE).Diageo had a market capitalisation of c. £22.6 billion as of the close ofbusiness of the London Stock Exchange on Tuesday, 29 March 2005. For moreinformation about Diageo, its people, brands and performance, visit us atwww.diageo.com 3. Headquartered in Basel, Switzerland, Roche is one of the world's leadingresearch-focused healthcare groups in the fields of pharmaceuticals anddiagnostics. As a supplier of innovative products and services for the earlydetection, prevention, diagnosis and treatment of disease, the Group contributeson a broad range of fronts to improving people's health and quality of life.Roche is a world leader in diagnostics, the leading supplier of medicines forcancer and transplantation and a market leader in virology. In 2004 sales by thePharmaceuticals Division totalled 21.7 billion Swiss francs, while theDiagnostics Division posted sales of 7.8 billion Swiss francs. Roche employsroughly 65,000 people in 150 countries and has R&D agreements and strategicalliances with numerous partners, including majority ownership interests inGenentech and Chugai. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Diageo